Business / Finance

RSS

Natera raises $55.5 million in funding led by Sofinnova Ventures

Natera, Inc., a leader in non-invasive genetic testing, today announced that it has raised approximately $55.5 million in funding led by Silicon Valley life sciences investment firm Sofinnova Ventures. This financing round also includes participation from Capital Research and Management, Franklin Templeton Investments, Jennison Associates, RA Capital Management, Healthcor Partners and OrbiMed Advisors.

From Natera 6 Apr 2015

Sanford-Burnham, Daiichi Sankyo sign licensing agreement to expand development of small molecule

Sanford-Burnham Medical Research Institute today announced that it has signed a licensing agreement to further develop a first-in-class small molecule with Daiichi Sankyo for the treatment of cardiovascular-metabolic disease.

6 Apr 2015

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).

6 Apr 2015

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.

6 Apr 2015

Radlink, DePuy Synthes sign exclusive worldwide sales agency agreement

Radlink, Inc., an emerging global leader in advanced medical imaging technology, announced today that it has signed an exclusive worldwide sales agency agreement with Johnson & Johnson subsidiary DePuy Synthes Companies. The contractual partnership provides for the exclusive worldwide distribution of Radlink's advanced imaging products, including the revolutionary Galileo Positioning System (GPS) featuring Surgeon's Checklist software, through DePuy Synthes Companies' sales representatives worldwide.

6 Apr 2015

Biotest Pharmaceuticals relocates its plasma collection center to San Antonio, Texas

Biotest Pharmaceuticals Corporation (BPC), a leading developer of immunology biotherapeutic products, is pleased to announce the relocation of its plasma collection center to 618 NW Loop 410 Suite 101 San Antonio, Texas.

3 Apr 2015

Pyrexar Medical procures hyperthermia assets of BSD Medical, begins operations

Pyrexar Medical begins operations today after completing the acquisition of hyperthermia assets held by Perseon, formerly BSD Medical. This acquisition includes substantially all hyperthermia assets, products, services and related intellectual property.

3 Apr 2015

Aptuit increases API capacity to meet increased demand for integrated candidate-to-IND solutions

Dr. Jonathan Goldman, CEO, Aptuit LLC, announced that Aptuit has increased its global capacity for Active Pharmaceutical Ingredient (API) Manufacture due to increased demand for API, and for its integrated and comprehensive candidate-to-IND development solution.

3 Apr 2015

Quest Diagnostics grants Supplier Excellence Awards to five companies

Quest Diagnostics, the world's leading provider of diagnostic information services, today awarded Supplier Excellence Awards to five companies at its 2015 Supplier Forum.

From Quest Diagnostics 2 Apr 2015

ImmunoClin receives controlled drug license to supply, produce schedule 1 drugs in UK

ImmunoClin Corporation, a healthcare company specialized in personalized medicine, announces that its wholly owned subsidiary, ImmunoClin Ltd., received a controlled drug license from the UK government to possess, supply and produce schedule 1 drugs in its UK laboratory.

2 Apr 2015

Myriad Genetics expands companion diagnostic collaboration with AstraZeneca

Myriad Genetics, Inc. today announced the expansion of its companion diagnostic collaboration with AstraZeneca. Under the terms of the expanded agreement, Myriad’s BRACAnalysis CDx test will be used to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with Lynparza (olaparib).

2 Apr 2015

Columbia Laboratories to adopt Juniper Pharmaceuticals brand marks

Columbia Laboratories, Inc., today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change will become effective Friday, April 10, 2015, and the Company's common stock will begin trading on the Nasdaq Stock Exchange under the new ticker symbol — "JNP" — on Monday, April 13, 2015.

2 Apr 2015

Novogen appoints PCG Advisory to manage investor-awareness program in the US

Novogen Ltd today announced it has appointed US-based public relations firm, PCG Advisory (PCG), to drive the Company's investor-awareness program in the US. PCG will be using their expertise in creating awareness and establishing key relationships within the US investment community via their targeted outreach campaign.

2 Apr 2015

BioLight forms strategic partnership with Rock-One to expand its presence within China

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today an agreement to enter into a strategic partnership with Rock-One International Holdings Ltd., a holding company specializing in investment activities, including in the high tech and biomedical industries.

2 Apr 2015

Helsinn's Swiss manufacturing subsidiary bags 2015 CMO Leadership Award

Helsinn, the Swiss Group focused on building quality cancer care, is pleased to announce that its Swiss manufacturing subsidiary, Helsinn Advanced Synthesis SA, has won a 2015 CMO Leadership Award, determined by contract manufacturing client research.

2 Apr 2015

MD Anderson, NanoString Technologies collaborate to accelerate development of 'multi-omic' assays

The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced a multi-year collaboration to accelerate the development and adoption of a new type of assay based on NanoString's nCounter Analysis System.

From NanoString Technologies 1 Apr 2015

Catasys' total revenues increase 169% to $2.0 million in 2014

Catasys, Inc., provider of proprietary health management services to health insurers and employers, today reported full year 2014 financial results for the period ended December 31, 2014.

1 Apr 2015

Hitachi Aloka Medical becomes exclusive global distributor of iVu Imaging’s SOFIA system

Hitachi Aloka Medical, Ltd. (Headquartered in Tokyo, Japan, President: Mr. Minoru Yoshizumi) and iVu Imaging Corporation announced the signing of an agreement making Hitachi Aloka Medical, Ltd. the exclusive global distributor of iVu’s SOFIA system, an automated whole breast ultrasound scanner designed to enable the earlier detection of breast cancer in women with mammographically dense breasts.

1 Apr 2015

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

Neurocrine Biosciences, Inc. today announced that it has entered into an exclusive collaboration and licensing agreement for the development and commercialization of its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets with Mitsubishi Tanabe Pharma Corporation.

1 Apr 2015

ATI Physical Therapy acquires Flexeon Rehabilitation

ATI Physical Therapy today announces the acquisition of Flexeon Rehabilitation, a 16 clinic practice with locations in Chicagoland and Northwest Indiana. ATI is the nation's largest physical therapy practice under one brand, and recently expanded into the state of Nevada with the addition of 12 clinics in the Las Vegas area.

31 Mar 2015

Business / Finance

Natera raises $55.5 million in funding led by Sofinnova Ventures

Sanford-Burnham, Daiichi Sankyo sign licensing agreement to expand development of small molecule

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Radlink, DePuy Synthes sign exclusive worldwide sales agency agreement

Biotest Pharmaceuticals relocates its plasma collection center to San Antonio, Texas

Pyrexar Medical procures hyperthermia assets of BSD Medical, begins operations

Aptuit increases API capacity to meet increased demand for integrated candidate-to-IND solutions

Quest Diagnostics grants Supplier Excellence Awards to five companies

ImmunoClin receives controlled drug license to supply, produce schedule 1 drugs in UK

Myriad Genetics expands companion diagnostic collaboration with AstraZeneca

Columbia Laboratories to adopt Juniper Pharmaceuticals brand marks

Novogen appoints PCG Advisory to manage investor-awareness program in the US

BioLight forms strategic partnership with Rock-One to expand its presence within China

Helsinn's Swiss manufacturing subsidiary bags 2015 CMO Leadership Award

MD Anderson, NanoString Technologies collaborate to accelerate development of 'multi-omic' assays

Catasys' total revenues increase 169% to $2.0 million in 2014

Hitachi Aloka Medical becomes exclusive global distributor of iVu Imaging’s SOFIA system

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

ATI Physical Therapy acquires Flexeon Rehabilitation

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News